Search

Your search keyword '"M. Tateyama"' showing total 512 results
Start Over Author "M. Tateyama"
512 results on '"M. Tateyama"'

17. SO-30 Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma

Author

K. Harada, T. Yamamura, O. Muto, M. Nakamura, S. Sogabe, K. Sawada, S. Nakano, M. Yagisawa, T. Muranaka, M. Dazai, M. Tateyama, K. Ito, R. Saito, Y. Kobayashi, S. Kato, T. Miyagishima, Y. Kawamoto, S. Yuki, Y. Sakata, N. Sakamoto, and Y. Komatsu

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

18. P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment

Author

M. Tateyama, Kentaro Sawada, Susumu Sogabe, Masafumi Nakamura, R. Matsumoto, Hiroshi Nakatsumi, Osamu Muto, Satoshi Yuki, Masayoshi Dazai, Akira Ueda, Shintaro Nakano, Hiroyuki Okuda, Yasuo Komatsu, Yasutsuna Sasaki, Tatsuya Kobayashi, Kazuteru Hatanaka, A. Sato, Takahide Sasaki, Masataka Yagisawa, K. Ito, Y. Sakata, and Atsushi Ishiguro

Subjects
Oncology, medicine.medical_specialty, Second line treatment, Bevacizumab, business.industry, Colorectal cancer, Retrospective cohort study, Hematology, medicine.disease, Irinotecan, Internal medicine, Medicine, In patient, business, medicine.drug
Published
2021
Full Text
View/download PDF

19. P-112 HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody

Author

Yoshito Komatsu, Hiroshi Nakatsumi, Kazuteru Hatanaka, Satoshi Yuki, Y. Sakata, Masayoshi Dazai, M. Katagiri, R. Takagi, Kazuaki Harada, Masahito Kotaka, M. Tateyama, Masafumi Nakamura, Yasutsuna Sasaki, Yoshimitsu Kobayashi, Yasuyuki Kawamoto, Osamu Muto, Yasushi Tsuji, Yoshiaki Shindo, Susumu Sogabe, Tatsuya Kobayashi, Atsushi Ishiguro, and Takahide Sasaki

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Hematology, medicine.disease, Refractory, Anti-EGFR Antibody, Internal medicine, medicine, FOLFIRI, In patient, Line (text file), business, Aflibercept, medicine.drug
Published
2020
Full Text
View/download PDF

20. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index

Author

Shintaro Nakano, Tomoyuki Ohta, Koichi Furukawa, Kyoko Kato, Kazuteru Hatanaka, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Shunsuke Kato, Junta Nakajima, Atsushi Ishiguro, Kazunori Eto, Takayuki Ando, Mari Sekiguchi, Satoshi Yuki, Yasuo Komatsu, Susumu Sogabe, Masafumi Nakamura, Kenji Suzuki, M. Tateyama, and Y. Sakata

Subjects
Oncology, medicine.medical_specialty, Index (economics), business.industry, Colorectal cancer, Internal medicine, medicine, Retrospective cohort study, In patient, Hematology, business, medicine.disease
Published
2018
Full Text
View/download PDF

21. HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)

Author

Kazuteru Hatanaka, Takenori Takahata, Shinya Minami, Minoru Uebayashi, N. Ehira, Takahide Sasaki, Masayoshi Dazai, Satoshi Yuki, M. Tateyama, Atsushi Sato, Masataka Yagisawa, Osamu Muto, Y. Sakata, Aya Tanimoto, Yasuo Komatsu, Yasuyuki Kawamoto, Ichiro Iwanaga, Shintaro Nakano, T. Wakabayashi, and Atsushi Ishiguro

Subjects
Oncology, medicine.medical_specialty, business.industry, Retrospective cohort study, Hematology, Neutropenia, medicine.disease, Gemcitabine, Internal medicine, Pancreatic cancer, medicine, Gastrointestinal cancer, Adverse effect, business, Febrile neutropenia, Cohort study, medicine.drug
Abstract

Background The regimens of nab-P+GEM have become available for advanced pancreatic cancer, especially metastatic disease. However, there are not enough data of nab-P+GEM for LAPC. Methods This is a retrospective multiple institutes cohort study using medical records of LAPC patients who received nab-P+GEM between January 2015 and September 2017. We have surveyed their characteristics and treatment outcomes. Results The number of relevant patients was 48 at 11 institutes. Median age was 68 years old, male/female : 22/26, ECOG PS 0/1/2 : 33/13/2, primary site; head/body/tail : 28/18/2. Relative dose intensity was nab-P; 0.588 (0.065-1.012) and GEM; 0.656 (0.368-1.012). Response rate was 27.0% and Disease control rate was 94.6% among patients who had target lesion. Median progression-free survival was 9.4 months (95% CI, 5.4 – 13.4) and median overall survival was 19.6 months (95% CI, 13.9 – 24.3). The most common adverse event of grade 3 or higher was neutropenia (61.7%). Febrile neutropenia was 8.3%. Conclusions It seemed that nab-P+GEM was effective for patients with LAPC. Prospective and further investigation in more cases is expected. Legal entity responsible for the study Hokkaido Gastrointestinal Cancer Study Group. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Published
2019
Full Text
View/download PDF

23. 172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Author

T. Ando, S. Yuki, H. Nakatsumi, T. Muranaka, A. Hosokawa, Y. Tsuji, M. Nakamura, O. Muto, T. Sasaki, I. Iwanaga, K. Hatanaka, A. Sato, K. Eto, K. Furukawa, M. Tateyama, Y. Takahashi, S. Sogabe, T. Honda, Y. Sakata, and Y. Komatsu

Subjects
Oncology, Hematology
Published
2016
Full Text
View/download PDF

25. HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

Author

M. Dazai, S. Yuki, K. Sawada, T. Muranaka, Y. Kawamoto, H. Nakatsumi, S. Nakano, A. Ishiguro, M. Tateyama, A. Sato, Y. Kobayashi, M. Nakamura, H. Okuda, Y. Takahashi, K. Eto, S. Muto, K. Hatanaka, T. Amano, Y. Sakata, and Y. Komatsu

Subjects
Oncology, Hematology
Published
2018
Full Text
View/download PDF

26. The prospective multicenter study of relation between 5-HIAA/substance P plasma concentration transition and nausea/vomiting in patients with gastrointestinal cancer receiving moderately emetogenic chemotherapy

Author

Atsushi Ishiguro, Kota Ono, M. Tateyama, Masayoshi Dazai, Shunsuke Ohnishi, T. Saiki, Masataka Yagisawa, Kentaro Sawada, Satoshi Yuki, Hiroshi Nakatsumi, Naoya Sakamoto, Tetsuhito Muranaka, Yasuo Komatsu, and Yasuyuki Kawamoto

Subjects
medicine.medical_specialty, Nausea vomiting, business.industry, Substance P, Hematology, medicine.disease, Gastroenterology, chemistry.chemical_compound, Oncology, Multicenter study, chemistry, Internal medicine, Plasma concentration, medicine, In patient, Gastrointestinal cancer, business, Emetogenic chemotherapy
Published
2018
Full Text
View/download PDF

27. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction

Author

T. Honda, S. Yuki, T. Muranaka, H. Nakatsumi, Y. Tsuji, T. Miyagishima, S. Yoshida, K. Hatanaka, T. Sasaki, A. Ishiguro, O. Muto, H. Ohnuma, S. Kato, A. Sato, M. Abe, K. Kato, K. Onodera, K. Eto, M. Tateyama, T. Amano, Y. Sakata, and Y. Komatsu

Subjects
Oncology, Hematology
Published
2018
Full Text
View/download PDF

29. HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

Author

Satoshi Yuki, Kazunori Eto, Hiroshi Nakatsumi, Yasuo Komatsu, M. Tateyama, Yoshimitsu Kobayashi, Masayoshi Dazai, Takuto Miyagishima, Atsushi Sato, Koshi Fujikawa, Y. Sakata, Kazuteru Hatanaka, Hiroyuki Okuda, Masataka Yagisawa, Tetsuhito Muranaka, T. Saiki, Toraji Amano, Yasuyuki Kawamoto, Atsushi Ishiguro, S. Muto, Takenori Takahata, and Masafumi Nakamura

Subjects
medicine.medical_specialty, Second line treatment, Colorectal cancer, business.industry, Hematology, Placebo, medicine.disease, Gastroenterology, Double blind, Diarrhea, medicine.anatomical_structure, Oncology, Internal medicine, medicine, In patient, Iris (anatomy), medicine.symptom, business
Published
2018
Full Text
View/download PDF

30. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility

Author

Y. Niki, T. Matsumoto, S. Kohno, N. Aoki, A. Watanabe, J. Sato, R. Hattori, M. Terada, N. Koashi, T. Kozuki, A. Maruo, K. Morita, K. Ogasawara, Y. Takahashi, J. Watanabe, K. Sunakawa, K. Totsuka, H. Hanaki, M. Yagisawa, K. Takeuchi, S. Fujimura, H. Takeda, H. Ikeda, N. Sato, K. Niitsuma, M. Saito, S. Koshiba, M. Kaneko, M. Miki, S. Nakanowatari, Y. Honda, J. Chiba, H. Takahashi, M. Utagawa, T. Kondo, A. Kawana, H. Konosaki, Y. Aoki, H. Ueda, H. Sugiura, M. Ichioka, H. Goto, D. Kurai, M. Okazaki, K. Yoshida, T. Yoshida, Y. Tanabe, S. Kobayashi, M. Okada, H. Tsukada, Y. Imai, Y. Honma, K. Nishikawa, T. Yamamoto, A. Kawai, T. Kashiwabara, Y. Takesue, Y. Wada, K. Nakajima, H. Toda, N. Mitsuno, H. Sugimura, S. Yoshioka, M. Kurokawa, Y. Munekawa, H. Nakajima, S. Kubo, Y. Ohta, K. Mikasa, K. Maeda, K. Kasahara, A. Koizumi, R. Sano, S. Yagi, M. Takaya, Y. Kurokawa, N. Kusano, E. Mihara, M. Kuwabara, Y. Fujiue, T. Ishimaru, N. Matsubara, Y. Kawasaki, H. Tokuyasu, K. Masui, K. Negayama, N. Ueda, M. Ishimaru, Y. Nakanishi, M. Fujita, J. Honda, J. Kadota, K. Hiramatsu, Z. Nagasawa, M. Suga, H. Muranaka, K. Yanagihara, J. Fujita, and M. Tateyama

Subjects
Adult, Microbiology (medical), Imipenem, Respiratory tract infection, Klebsiella pneumoniae, Resistance, Microbial Sensitivity Tests, Biology, medicine.disease_cause, Gram-Positive Bacteria, Microbiology, Haemophilus influenzae, Moraxella catarrhalis, Japan, Ampicillin, Streptococcus pneumoniae, Drug Resistance, Bacterial, Gram-Negative Bacteria, medicine, Humans, Pharmacology (medical), Respiratory Tract Infections, Surveillance, Bacterial Infections, biology.organism_classification, Anti-Bacterial Agents, Ciprofloxacin, Infectious Diseases, Amikacin, Susceptibility, medicine.drug
Abstract

For the purpose of a nationwide surveillance of the antimicrobial susceptibility of bacterial respiratory pathogens in patients in Japan, the Japanese Society of Chemotherapy conducted their second year survey, during the period from January to August, 2007. A total of 1178 strains were collected from clinical specimens obtained from adult patients with well-diagnosed respiratory tract infections. Susceptibility testing was evaluable for 1108 strains (226 Staphylococcus aureus, 257 Streptococcus pneumoniae, 6 Streptococcus pyogenes, 206 Haemophilus influenzae, 120 Moraxella catarrhalis, 122 Klebsiella pneumoniae, and 171 Pseudomonas aeruginosa). A total of 44 antibacterial agents, including 26 beta-lactams (four penicillins, three penicillins in combination with beta-lactamase inhibitors, four oral cephems, eight parenteral cephems, one monobactam, five carbapenems, and one penem), three aminoglycosides, four macrolides (including ketolide), one lincosamide, one tetracycline, two glycopeptides, six fluoroquinolones, and one oxazolidinone were used for the study. Analysis was conducted at the central reference laboratory according to the method recommended by the Clinical and Laboratory Standards Institute (CLSI). The incidence of methicillinresistant Staphylococcus aureus (MRSA) was high, at 59.7%, and the incidences of penicillin-intermediateresistant and -resistant Streptococcus pneumoniae (PISP and PRSP) were 30.4% and 5.1%, respectively. Among Haemophilus influenzae strains, 19.9% of them were found to be beta-lactamase-non-producing ampicillin (ABPC)-intermediately-resistant (BLNAI), 29.1% to be beta-lactamasenon-producing ABPC-resistant (BLNAR), and 6.7% to be beta-lactamase-producing ABPC-resistant (BLPAR) strains. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae was not isolated. Two isolates (1.2%) of Pseudomonas aeruginosa were found to be metallo-beta-lactamase-producing strains, including one (0.6%) suspected multidrug-resistant strain showing resistance to imipenem, amikacin, and ciprofloxacin. These data will be a useful reference for future periodic surveillance studies and for investigations to control resistant infections as well. Continued surveillance is required to prevent the further spread of these antimicrobial resistances.

Published
2009
Full Text
View/download PDF

31. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility

Author

Y. Niki, H. Hanaki, M. Yagisawa, S. Kohno, N. Aoki, A. Watanabe, J. Sato, R. Hattori, N. Koashi, T. Kozuki, A. Maruo, K. Morita, K. Ogasawara, Y. Takahashi, J. Watanabe, K. Totsuka, K. Takeuchi, M. Takahashi, H. Takeda, H. Ikeda, H. Kaneda, K. Niitsuma, M. Saito, S. Koshiba, M. Kaneko, S. Itabashi, M. Miki, S. Nakanowatari, Y. Honda, J. Chiba, H. Takahashi, M. Utagawa, T. Kondo, A. Kawana, H. Konosaki, Y. Aoki, N. Chonabayashi, H. Ueda, H. Sugiura, M. Ichioka, H. Goto, M. Aoshima, M. Okazaki, T. Ozawa, F. Horiuchi, T. Yoshida, H. Tsukada, S. Kobayashi, H. Yoshikawa, Y. Imai, Y. Honma, K. Yoshida, M. Takaya, Y. Kurokawa, M. Kuwabara, Y. Fujiue, T. Ishimaru, N. Matsubara, Y. Kawasaki, H. Tokuyasu, K. Masui, E. Shimizu, K. Yoneda, K. Negayama, N. Ueda, M. Ishimaru, Y. Nakanishi, M. Fujita, J. Honda, J. Kadota, K. Hiramatsu, Z. Nagasawa, M. Suga, H. Muranaka, K. Yanagihara, J. Fujita, and M. Tateyama

Subjects
Microbiology (medical), Respiratory tract infection, Klebsiella pneumoniae, Respiratory Tract Diseases, Resistance, Drug resistance, medicine.disease_cause, Haemophilus influenzae, Microbiology, Moraxella catarrhalis, Japan, Drug Resistance, Multiple, Bacterial, Ampicillin, Streptococcus pneumoniae, Humans, Medicine, Pharmacology (medical), Gram-Positive Bacterial Infections, Ketolide, Surveillance, Respiratory tract infections, biology, business.industry, biology.organism_classification, Infectious Diseases, Susceptibility, Population Surveillance, Drug, Gram-Negative Bacterial Infections, business, medicine.drug
Abstract

The Japanese Society of Chemotherapy (JSC) conducted the first nationwide surveillance of bacterial respiratory pathogens during the period from January to August 2006. With the cooperation of 32 medical institutions throughout Japan, a total of 924 strains belonging to seven clinically relevant bacterial species were collected from adult patients with well-diagnosed respiratory tract infections (RTIs). Antimicrobial susceptibility testing of the 887 evaluable strains (205 Staphylococcus aureus, 200 Streptococcus pneumoniae, 9 Streptococcus pyogenes, 165 Haemophilus influenzae, 91 Moraxella catarrhalis, 74 Klebsiella pneumoniae, and 143 Pseudomonas aeruginosa) to 42 antibacterial agents was conducted at the Central Laboratory of the Research Center for Anti-infective Drugs of the Kitasato Institute, according to recommendations issued by the Clinical and Laboratory Standards Institute (CLSI). The antibacterial agents employed were 25 beta-lactams, three aminoglycosides, four macrolides (including one azalide and one ketolide), one lincosamide, one tetracycline, two glycopeptides, five fluoroquinolones, and one oxazolidinone. The incidence of methicillin-resistant S. aureus (MRSA) was 63.4%, and the incidences of penicillin-intermediately resistant S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae (PRSP) were 35.0% and 4.0%, respectively. Among H. influenzae, 21.2% of the strains were found to be beta-lactamase-nonproducing ampicillin (ABPC)-intermediately resistant (BLNAI), 29.1% to be beta-lactamase-nonproducing ABPC-resistant (BLNAR), and 4.8% to be beta-lactamaseproducing ABPC-resistant (BLPAR) strains. The incidence of extended-spectrum beta-lactamase-producing K. pneumoniae was 2.7% (2 of 74 strains). Three (2.1%) of the 143 P. aeruginosa strains were found to be metallo-beta-lactamaseproducing, including 1 (0.7%) multidrug-resistant strain. Through the nationwide surveillance, we obtained fundamental antimicrobial susceptibility data of clinically relevant bacterial pathogens in adult RTI to various antibacterial agents. These data will be a useful reference for future periodic surveillance studies, as well as for investigations to control antimicrobial-resistant pathogens.

Published
2008
Full Text
View/download PDF

32. Changes in oxalate and some mineral concentrations of Setaria sphacelata under cutting and uncutting conditions

Author

M. Tateyama, Ramli Bin Abdullah, Mitsuhiro Niimi, Osamu Kawamura, Mohammad Mijanur Rahman, and W. E. Wan Khadijah

Subjects
Setaria, Sodium, Potassium, Mineral deficiency, Setaria Plant, chemistry.chemical_element, Forage, Oxalate, chemistry.chemical_compound, Cutting, Animal science, medicine, Animals, Regeneration, Magnesium, Minerals, biology, Plant Stems, Oxalic Acid, Setaria sphacelata, Ruminants, biology.organism_classification, medicine.disease, Animal Feed, Plant Leaves, chemistry, Agronomy, Solubility, Seasons, Agronomy and Crop Science
Abstract

Oxalate concentration in forage plants is important, because it results mineral deficiency in ruminants. Data on oxalate concentration in forage plants in conjunction with cutting and uncutting conditions throughout the growing period are limited. This study was aimed to investigate the changes in oxalate and some mineral concentrations of setaria (Setaria sphacelata). The plants were harvested at different stages (vegetative, boot, pre-flowering, flowering and seed) of maturity and at about 50 cm in length of regrowth (second to sixth cuttings) for evaluation of soluble oxalate, insoluble oxalate and some mineral concentrations. Soluble oxalate and total oxalate concentrations, as well as mineral concentrations, decreased with advancing maturity. Both oxalate concentrations (soluble or insoluble) were higher in leaf compared to stem. Soluble oxalate and total oxalate concentrations of regrowth were the highest at third cutting and lowest at sixth cutting. Insoluble oxalate concentration of regrowth was almost similar in all cuttings, except for the sixth cutting. The highest concentrations of potassium, sodium and magnesium of regrowth were observed at third cutting, while the highest concentration of calcium was observed at sixth cutting. A relationship between oxalate and mineral concentrations was partially observed. Results suggest that cutting materials of setaria from June to October could achieve oxalate levels that are toxic to ruminants.

Published
2015

35. 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV

Author

Masato Nakamura, Minoru Uebayashi, Tetsuhito Muranaka, Kencho Miyashita, Susumu Sogabe, Shunsuke Kato, Ichiro Iwanaga, Takeshi Kato, M. Tateyama, Kazunori Eto, Yuh Sakata, Masatoshi Kudo, Satoshi Yuki, Yoshito Komatsu, Hiroshi Nakatsumi, Takashi Meguro, Kazuteru Hatanaka, Naoya Sakamoto, Yasuyuki Kawamoto, and Hiroyuki Okuda

Subjects
Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, medicine.medical_treatment, medicine.disease, Oxaliplatin, Internal medicine, medicine, business, Cohort study, medicine.drug
Published
2015
Full Text
View/download PDF

37. THE GUIDELINE FOR RESTORING SETUP FROM EARTHQUAKE DISASTER ALONG JR-TOHKAIDOH LINE BETWEEN SETTSUMOTOYAMA AND SUMIYOSHI

Author

M. Tateyama, Y. Ichishi, T. Inui, and K. Kuribayashi

Subjects
Engineering, geography, geography.geographical_feature_category, business.industry, Sheet pile, Line (geometry), Earthquake disaster, Geotechnical engineering, General Medicine, business, Retaining wall, Levee
Abstract

The embankment of JR-Tohkaidoh line beween Settsumotoyama and Sumiyoshi was destroyed by the earthquake of Hyogo south area on January 17th 1995. The line runs east and west on the embankment on the formar river lied north and south.The embankment was supported mainly by the stone-piled retaining wall. The face of slope covered with concrete blocks was destroyed completely. Most of the retaining walls were clacked and, above all, some of them were devided in two pieces.For the purpose of opening the two inside lines earlier, which was little damaged, and besides restoring the trucks of the two outside lines, the erection fixture was done. It obliged the embankment to be shut out by sheet pile. In order to improve this problem, we decided to take RRR method, which effected sufficiently also for this earthquake, and as the length to lay the reiforced segument could not be enough, we adopted radish-anchor method.This report shows the guideline of our restoring this damaged embankment.

Published
1996
Full Text
View/download PDF

38. 172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Author

Y. Takahashi, Eto, Yoshito Komatsu, Koichi Furukawa, Tetsuhito Muranaka, Satoshi Yuki, Takuya Honda, M. Tateyama, Takahide Sasaki, Yasushi Tsuji, Takayuki Ando, Atsushi Sato, Ichiro Iwanaga, Ayumu Hosokawa, Hiroshi Nakatsumi, Masafumi Nakamura, Osamu Muto, Kazuteru Hatanaka, and Y. Sakata

Subjects
Oncology, Irinotecan/S-1, medicine.medical_specialty, Second line treatment, Cetuximab, business.industry, Colorectal cancer, Wild type, Hematology, medicine.disease_cause, medicine.disease, Internal medicine, Medicine, In patient, KRAS, business, medicine.drug
Published
2016
Full Text
View/download PDF

39. P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

Author

Ayumu Hosokawa, Naoya Sakamoto, Hiroshi Nakatsumi, Yasushi Tsuji, Yoshito Komatsu, Kazunori Eto, M. Tateyama, Yasuyuki Kawamoto, Atsushi Sato, Satoshi Yuki, Masafumi Nakamura, Susumu Sogabe, Koichi Furukawa, Kazuteru Hatanaka, Osamu Muto, Kentaro Sawada, Y. Sakata, Takuya Honda, Y. Takahashi, Tetsuhito Muranaka, Takahide Sasaki, and Ichiro Iwanaga

Subjects
Oncology, Irinotecan/S-1, medicine.medical_specialty, Second line treatment, Cetuximab, business.industry, Wild type, Phases of clinical research, Hematology, medicine.disease_cause, Irinotecan, Abstracts, Internal medicine, medicine, In patient, KRAS, business, medicine.drug
Published
2016
Full Text
View/download PDF

42. The effect of ground improvement by geotextiles

Author

K. Otake, T. Hayashi, M. Tateyama, T. Katanoda, T. Nakaya, and O. Murata

Subjects
Engineering, geography, geography.geographical_feature_category, Stress effects, business.industry, General Earth and Planetary Sciences, Geotechnical engineering, Structural engineering, business, Levee, General Environmental Science, Stress concentration
Abstract

This report presents the spring value's improvement of embankment which are reinforced which geotextites the basement of embankment are soft-ground improved by stakes, the insitu test consists of static and dynamic roading.As a result, it showes more efficient strength and more stress concentration to the top of stakes than no reinforced one. But the relation between ground and top of stakes is impossible to realize the dependence of stess strength and the assigneed stress effect is smaller than it by design.

Published
1990
Full Text
View/download PDF

43. 158P A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer; The HGCSG1401 study -first report

Author

Osamu Muto, Kazunori Eto, Yasushi Tsuji, Y. Sakata, Atsushi Ishiguro, Kei Onodera, Kyoko Kato, Yumiko Ohta, Satoshi Yuki, Kazuteru Hatanaka, Shuntaro Yoshida, Hiroyuki Okuda, Tomoyuki Ohta, Yoshito Komatsu, Masayoshi Dazai, M. Tateyama, Masafumi Nakamura, Atsushi Sato, Tetsuhito Muranaka, and Yasushi Sato

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Retrospective cohort study, Hematology, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Regorafenib, medicine, In patient, business
Published
2015
Full Text
View/download PDF

44. 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV

Author

Satoshi Yuki, Hiroshi Nakatsumi, Yoshito Komatsu, Takashi Meguro, Kazuteru Hatanaka, Kazunori Eto, M. Tateyama, Y. Sakata, Ichiro Iwanaga, Minoru Uebayashi, Susumu Sogabe, Masafumi Nakamura, Masatoshi Kudo, Hiroyuki Okuda, Kyoko Kato, T. Kato, Kentaro Sawada, Kencho Miyashita, Takuto Miyagishima, and Naoya Sakamoto

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Bevacizumab, Colorectal cancer, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Chemotherapy regimen, Oxaliplatin, Internal medicine, medicine, business, medicine.drug, Cohort study
Published
2015
Full Text
View/download PDF

45. 157P Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type mCRC: Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP/HGCSG1001: updated analysis of anti-tumor efficacy

Author

N. Ehira, Yoshito Komatsu, Takuto Miyagishima, Hiroshi Nakatsumi, Satoshi Yuki, M. Tateyama, Yoshimitsu Kobayashi, Riichiro Abe, Naoya Sakamoto, Yasushi Tsuji, H. Hisai, Ichiro Iwanaga, Masafumi Nakamura, Y. Sakata, Kazuteru Hatanaka, Koji Oba, Masatoshi Kudo, Hiroyuki Okuda, Hiraku Fukushima, and Tetsuhito Muranaka

Subjects
Oncology, Antitumor activity, medicine.medical_specialty, business.industry, Wild type, Hematology, Pharmacology, medicine.disease_cause, law.invention, Skin toxicity, Randomized controlled trial, law, Internal medicine, medicine, Panitumumab, KRAS, business, Third line treatment, medicine.drug
Published
2015
Full Text
View/download PDF

46. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy

Author

Hiraku Fukushima, Yasushi Tsuji, Kazuteru Hatanaka, T. Tagaki, Satoshi Yuki, H. Hisai, M. Tateyama, Yuh Sakata, Masatoshi Kudo, K. Sawada, Yoshito Komatsu, R. Abe, T. Miyagishima, Ichiro Iwanaga, Yoshimitsu Kobayashi, Hiroyuki Okuda, Yasuyuki Kawamoto, Masahiko Koike, Masato Nakamura, and N. Ehira

Subjects
Antitumor activity, Oncology, Cancer Research, medicine.medical_specialty, Colorectal cancer, business.industry, Wild type, medicine.disease, medicine.disease_cause, law.invention, Skin toxicity, Randomized controlled trial, law, Internal medicine, medicine, Panitumumab, KRAS, business, Third line treatment, medicine.drug
Published
2015
Full Text
View/download PDF

47. P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment

Author

Ayumu Hosokawa, S. Yokoyama, Hiroshi Nakatsumi, Masafumi Nakamura, Koichi Furukawa, Ichiro Iwanaga, M. Tateyama, Atsushi Sato, Yoshito Komatsu, Osamu Muto, Yasushi Tsuji, Satoshi Yuki, Takuya Honda, Kazunori Eto, Y. Takahashi, Hiroyuki Okuda, Masayoshi Dazai, Masatoshi Kudo, M. Onodera, Takashi Meguro, Kazuteru Hatanaka, and Y. Sakata

Subjects
Oncology, medicine.medical_specialty, Second line treatment, Cetuximab, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease_cause, medicine.disease, Irinotecan, medicine.anatomical_structure, Internal medicine, medicine, In patient, KRAS, Iris (anatomy), business, medicine.drug
Published
2015
Full Text
View/download PDF

48. P-271 Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients: The HGCSG1401 Study -First Report

Author

Kazuteru Hatanaka, Atsushi Ishiguro, Yasushi Tsuji, Satoshi Yuki, Masakazu Abe, Shuntaro Yoshida, Hiroyuki Okuda, K. Yoshizaki, Shunsuke Kato, Y. Sakata, Tetsuhito Muranaka, Kei Onodera, Yoshito Komatsu, Kazunori Eto, Masafumi Nakamura, Yumiko Ohta, Osamu Muto, Naoya Sakamoto, Yasuyuki Kawamoto, M. Tateyama, Atsushi Sato, and Yasushi Sato

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Retrospective cohort study, Hematology, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Regorafenib, medicine, business
Published
2015
Full Text
View/download PDF

49. HRCT shows variations in appearance in disseminated tuberculosis in adults

Author

J, Fujita, S, Bandoh, A, Kubo, T, Ishii, N, Kanaji, H, Nakamura, F, Higa, M, Tateyama, and T, Ishida

Subjects
Aged, 80 and over, Male, Disease Progression, Humans, Reproducibility of Results, Female, Middle Aged, Tomography, X-Ray Computed, Severity of Illness Index, Tuberculosis, Pulmonary, Aged, Retrospective Studies
Abstract

To examine patterns of high resolution computed tomography (HRCT) of lungs of adults with disseminated tuberculosis (TB).Disseminated TB was defined as radiological involvement of all lung lobes.The case series illustrated wide variation in HRCT of disseminated TB. Patterns identified on HRCT included (1) miliary TB (haematogenous dissemination), (2) miliary TB with exudative reaction, (3) bronchogenic spread, (4) miliary TB mixed with bronchogenic spread, and (5) bronchogenic spread with multiple cavity formation.The HRCT patterns described allow classification of disseminated TB according to the mechanism of spread (haematogenous and/or bronchogenic) and the degree of local lung involvement (reaction or cavitation).

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results